Amgen Inc. (AMGN) Q3 2022 Earnings Results

Amgen Beats on EPS, Stock Down 1.16%

Amgen's earnings report showed a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by 1.16%, likely due to the lack of revenue data and guidance, which may have left investors uncertain about future performance. The cautious tone from management may have also contributed to the stock's decline.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$4.70	N/A	+6.17%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism about future growth. They pointed to strong product performance while recognizing market challenges.

Management highlighted strong performance in key therapeutic areas.

They acknowledged ongoing challenges in the market but expressed confidence in their pipeline.

The team emphasized their commitment to innovation and patient access.

Amgen Beats on EPS, Stock Down 1.16%

Key numbers

Management commentary

Amgen Inc.

More earnings this week

Amgen Beats on EPS, Stock Down 1.16%

Key numbers

Management commentary